Overview

An Efficacy and Safety Study of Jacktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Status:
Not yet recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.

Phase:

Phase 2

Details

Lead Sponsor:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd